Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
NCT04810598
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Renal Disease
Interventions
DRUG:
Venetoclax
Sponsor
AbbVie
Collaborators
[object Object]